Stay updated with breaking news from Enterprising Science. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Most approved gene therapies today, including those involving CRISPR-Cas9, work their magic on cells removed from the body, after which the edited cells are returned to the patient.
<p>By attaching two kinds of antibody fragments to membrane-derived globules, UC Berkeley researchers selectively delivered CRISPR-Cas9, guide RNA and a transgene to T-cells in living mice to create CAR T-cells. While this technique could make it easier to create CAR T-cells <em>in vivo</em> for cancer therapy, the ultimate goal is to selectively target CRISPR-filled "enveloped delivery vehicles" to any type of cell and avoid the <em>ex vivo</em> cell editing now used in current gene therapies.</p>
Jennifer Doudna answers our questions.
WIES fellows will have access to successful female entrepreneurs, including CRISPR pioneer and Nobel laureate Jennifer Doudna, who founded the IGI.